288 related articles for article (PubMed ID: 34268454)
1. Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.
Yuen KCJ; Mortensen MJ; Azadi A; Fonkem E; Findling JW
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00246. PubMed ID: 34268454
[TBL] [Abstract][Full Text] [Related]
2. Adrenal Insufficiency: Immune Checkpoint Inhibitors and Immune-Related Adverse Event Management.
Hobbs KB; Yackzan S
Clin J Oncol Nurs; 2020 Jun; 24(3):240-243. PubMed ID: 32441673
[TBL] [Abstract][Full Text] [Related]
3. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 pandemic and adrenals: deep insights and implications in patients with glucocorticoid disorders.
Cozzolino A; Hasenmajer V; Newell-Price J; Isidori AM
Endocrine; 2023 Oct; 82(1):1-14. PubMed ID: 37338722
[TBL] [Abstract][Full Text] [Related]
5. Adrenal Insufficiency and Glucocorticoid Use During the COVID-19 Pandemic.
Almeida MQ; Mendonca BB
Clinics (Sao Paulo); 2020; 75():e2022. PubMed ID: 32555949
[TBL] [Abstract][Full Text] [Related]
6. A case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors.
Yeung SJ; Qdaisat A; Bischof JJ; Caterino JM; Kyriacou DN; Coyne Md C
Am J Emerg Med; 2024 Jun; 80():227.e1-227.e5. PubMed ID: 38705758
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
8. Risk assessment, diagnosis, and treatment of cancer treatment-related adrenal insufficiency.
Hayes AG; Rushworth RL; Torpy DJ
Expert Rev Endocrinol Metab; 2022 Jan; 17(1):21-33. PubMed ID: 34979842
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Manaka K; Sato J; Takeuchi M; Watanabe K; Kage H; Kawai T; Sato Y; Miyagawa T; Yamada D; Kume H; Sato S; Nagase T; Iiri T; Nangaku M; Makita N
Sci Rep; 2021 Jun; 11(1):11617. PubMed ID: 34078988
[TBL] [Abstract][Full Text] [Related]
10. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
11. Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.
Kotwal A
Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):427-434. PubMed ID: 34183541
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
[TBL] [Abstract][Full Text] [Related]
13. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis.
Bando H; Yamamoto M; Urai S; Motomura Y; Sasaki Y; Ohmachi Y; Kobatake M; Tsujimoto Y; Oi-Yo Y; Suzuki M; Yamamoto N; Takahashi M; Fukuoka H; Iguchi G; Ogawa W
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38418395
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: A retrospective cohort study.
Cai Q; Wu W; Li R; Li X; Xu Q; Zhao L; Lv Q
Int Immunopharmacol; 2024 Jan; 127():111337. PubMed ID: 38064811
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-Induced Adrenalitis and Primary Adrenal Insufficiency: Systematic Review and Optimal Management.
Shi Y; Shen M; Zheng X; Yang T
Endocr Pract; 2021 Feb; 27(2):165-169. PubMed ID: 33554872
[TBL] [Abstract][Full Text] [Related]
16. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
17. Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study.
Takayasu S; Mizushiri S; Watanuki Y; Yamagata S; Usutani M; Nakada Y; Asari Y; Murasawa S; Kageyama K; Daimon M
Sci Rep; 2022 Jan; 12(1):1294. PubMed ID: 35079086
[TBL] [Abstract][Full Text] [Related]
18. Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects.
Martella S; Lucas M; Porcu M; Perra L; Denaro N; Pretta A; Deias G; Willard-Gallo K; Parra HS; Saba L; Scartozzi M; Wekking D; Kok M; Aiello MM; Solinas C
Semin Oncol; 2023 Dec; 50(6):144-148. PubMed ID: 38151399
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibition in COVID-19: risks and benefits.
Pezeshki PS; Rezaei N
Expert Opin Biol Ther; 2021 Sep; 21(9):1173-1179. PubMed ID: 33543652
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
Hijmering-Kappelle LBM; Hiltermann TJN; Bensch F
Clin Lung Cancer; 2022 Mar; 23(2):143-150. PubMed ID: 35034861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
